Pfizer BioNTech is now working to release their new experimental oral drug to treat COVID-19 at the first sign of illness and it could be available in both public and private sector by the end of the year, CEO Albert Bourla told CNBC on Tuesday.
Pfizer BioNTech, a U.S and German biopharmaceutical company, began their first clinical trial in March testing their new antiviral therapy for the disease. The drug is part of a class of medicines called protease inhibitors and works by inhibiting an enzyme that the virus needs to replicate in human cells, CNBC said.
If clinical trial goes well and the Food and Drug Administration approves it, the drug can be distributed across the United States and other countries, CEO Albert told CNBC.
Health Undersecretary Rosario Vergeire, for her part, said they will be looking into the study. She added that once Pfizer completes its clinical trials and finds that the drug is effective, the Philippines will get access to the pill, GMA News said on their report.
Sources:
GMA News
CNBC News
No comments:
Post a Comment